Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36

Benzinga Newsdesk www.benzinga.com Negative 92.2%

Neg 92.2% Neu 0% Pos 0%

Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers the price target from $38 to $36.